Switching to Iloperidone From Other Antipsychotics in Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

iloperidone

Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.

Trial Locations (59)

10305

Behavioral Medical Research, Staten Island

10312

Richmond Behavioral Associates, Staten Island

11004

Division of Psychiatry Research - Zucker Hills Hospital, Glen Oaks

11366

Comprehensive Neuroscience, Fresh Meadows

11516

Neurobehavioral Research, Cedarhurst

14618

Finger Lakes Clinical Research, Rochester

19131

Belmont Center for Comprehensive Treatment, Philadelphia

19139

CRI Worldwide, LLC - Kirkbride Division, Philadelphia

20016

Comprenhensive Neuroscience, Washington D.C.

29407

Carolina Clinical Trials, Charleston

30060

Northwest Behavioral Research Center, Marietta

30080

Carman Research, Smyrna

Institute for Behavioral Medicine, Smyrna

30308

Atlanta Center for Medical Research, Atlanta

30328

Comprehensive Neuroscience, Atlanta

32256

Amit K. Vijapura MD & Associates, Jacksonville

33161

Scientific Clinical Research, North Miami

35226

Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham

39232

Precise Research Centers, Flowood

44122

North Coast Clinical Trials, Beachwood

44718

Neurobehavioral Clinical Research, Canton

48302

Neurobehavioral Medicine Group, Clinical Trials Division, Bloomfield Hills

48307

Rochester Center for Behavioral Medicine, Rochester Hills

60005

Alexian Brothers Center for Mental Health, Arlington Heights

60181

Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace

60563

AMR - Baber Research, Inc., Naperville

60612

Rush University Medical Center, Treatment Research Center, Chicago

University of Illinois at Chicago, Chicago

63301

St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles

71115

Louisiana Clinical Research, Shreveport

73103

IPS Research Company, Oklahoma City

73112

SP Research, PLLC, Oklahoma City

75062

Mary Ann Knesevich, MD, PA, Irving

75074

InSite Clinical Research, Plano

75115

InSite Clinical Research, DeSoto

75230

KRK Medical Research, Dallas

75231

FutureSearch Trials, Dallas

77007

Bayou City Research Limited, Houston

77008

Claghorn-Lesem Research Clinic, Inc, Houston

78754

Community Clinical Research, Inc., Austin

87109

Albuquerque Neuroscience, Albuquerque

90502

Collaborative Neuroscience, Torrance

90703

Comprehensive Neuroscience, Cerritos

90813

Apostle Clinical Trials, Inc., Long Beach

91950

Pacific Health Systems, National City

92056

Excell Research, Inc., Oceanside

92102

CNRI San Diego, San Diego

92108

Affiliated Research Institute, San Diego

Artemis Institute for Clinical Research, San Diego

92591

Viking Clinical Research, Temecula

92626

ATP Clinical Research Center, Inc., Costa Mesa

92701

Neuropsychiatric Research Center of Orange County, Santa Ana

92845

Collaborative Neuroscience Network, Garden Grove

92868

University of California, Irvine, Orange

94612

Pacific Research Partners, Oakland

99204

Frontier Institute, Spokane

06052

The Hospital of Central Connecticut, New Britain

08002

Center for Emotional Fitness, Cherry Hill

08046

CRI World Wide Clinical Research Company, Willingboro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY